Oscar-winning actor F. Murray Abraham joins Morning Joe to discuss appearing in 'Beckett Briefs,' an off-Broadway show ...

Spravato is now the first stand-alone therapy for treatment-resistant depression, for patients who haven't responded to oral ...

She included a list of links to articles she’d been featured in as an expert. But her email address, which used the domain ...

Likewise, the coffee machine needs to be a Waitrose-branded self-serve coffee machine, as the offer doesn’t stand inside any ...

Decided to add this retail giant to your portfolio? Here's what you need to know before buying Amazon stock. Many, or all, of the products featured on this page are from our advertising partners ...

FDA halts Atara's EBVALLO and ATA3219 trials over manufacturing issues. Atara eyes $60 million milestone from Pierre Fabre upon EBVALLO approval.

Goldman has a buy rating and $325.40 price target on CSL's shares. This implies potential upside of 19% for investors over ...

Netflix Inc.’s stock was flat Friday after Benchmark analysts reiterated their sell rating on the stock even as they raised their price target by 30%, arguing that it’s looking overvalued in a ...

According to InvestingPro analysis, the company's stock currently trades below its ... the company is advancing its post-transplant TCR-T therapy program, with plans to initiate a pivotal study ...

Arcellx, Inc. (NASDAQ:ACLX) is primarily a cell therapy-focused biotech working ... Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies ...

US reg­u­la­tors have re­ject­ed a T cell ther­a­py for a rare and se­ri­ous trans­plant com­pli­ca­tion re­lat­ed to Ep­stein-Barr virus from Atara Bio­ther­a­peu­tics and ...